Anna Orduña Dolado

1 month ago | alz-journals.onlinelibrary.wiley.com | Shorena Janelidze |Nicholas Ashton |Ulrika Nordstrom |Anna Orduña Dolado

1 BACKGROUND Cerebrospinal fluid (CSF) tests for amyloid beta (Aβ) peptides (Aβ42 and Aβ40) and phosphorylated tau-181 (p-tau181) have been used for several decades as biomarkers of Alzheimer's disease (AD).1 More recently, CSF p-tau181/Aβ42 and Aβ42/Aβ40 were approved by the U.S. Food and Drug Administration (FDA) to diagnose AD.2-4 Furthermore, during the past 4 years, blood-based p-tau biomarkers of AD (and p-tau217, in particular) have been applied extensively in research settings and...